Efficacy Study of A Lotion to Prevent Common Colds

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2009 by The Dial Corporation.
Recruitment status was  Active, not recruiting
Sponsor:
Collaborator:
Hill Top Research
Information provided by:
The Dial Corporation
ClinicalTrials.gov Identifier:
NCT00993759
First received: October 8, 2009
Last updated: October 9, 2009
Last verified: October 2009
  Purpose

The purpose of this of this study is to determine if 3804-250A can prevent the common cold caused by the rhinovirus when applied to the hands. The study will also evaluate whether 3804-250A can prevent rhinovirus infection or common cold illnesses.

The study will also evaluate the safety of 3804-250A.


Condition Intervention Phase
Common Cold
Healthy
Drug: 3804-250A
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Phae 2 Efficacy Trial of AV Lotion for the Prevention of Cold Illness in Human Subjects

Resource links provided by NLM:


Further study details as provided by The Dial Corporation:

Primary Outcome Measures:
  • Reduction of rhinovirus-induced common colds. [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Reduction of rhinovirus infections and reduction of common colds. [ Time Frame: 9 weeks ] [ Designated as safety issue: No ]

Enrollment: 212
Study Start Date: August 2009
Estimated Study Completion Date: December 2009
Estimated Primary Completion Date: November 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
No Intervention: No treatment
Experimental: 3804-250A lotion Drug: 3804-250A
3.2 ml applied topically after hand washing and at least every 3 hours while awake.

Detailed Description:

Rhinovirus infections are the most frequent cause of up to 80% of cold illness during the fall rhinovirus season. While viral upper respiratory tract infections are generally mild and self-limiting, they are associated with an enormous economic burden, both in lost productivity and in expenditures for treatment. Rhinovirus infection is frequently associated with medical complications that have substantial morbidity such as acute otitis media and exacerbation of asthma.

Marketed treatment options for common colds consist primarily of symptomatic cold remedies that have only most effects on specific cold symptoms. 3804-250A is a topical treatment under investigation for the prevention of rhinovirus-associated colds by interruption of person-to-person transmission.

The study is a randomized trial conducted during a 9-week period during the fall rhinovirus epidemic season. Healthy, normal subjects will be randomly assigned to one of two treatment groups:

  1. AV Lotion or
  2. No Treatment control.

Subjects in the 3804-250A group will use the treatment on a defined schedule. The No Treatment control group will maintain their regular hand washing routine.

All subjects will record the presence of cold illness symptoms daily. Subjects will return to the study site weekly during the study for specimen collection for rhinovirus PCR, evaluation of irritation, review and clarification of study diary entries, for review and assessment of compliance, collection of adverse events and replenishment of study supplies. In addition, for the first five weeks of the study, subjects in the AV Lotion group will attend a second weekly compliance visits in which diaries and test product consumption will be assessed for compliance and collection of adverse events. Photographs of the hands will be taken for subjects who are withdrawn for skin irritation. The incidence of cold illness, rhinovirus-associated cold illness and rhinovirus infection will be compared between the treatment groups.

  Eligibility

Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Read and sign a copy of the approved Consent Form;
  • 18-40 years of age;
  • If a woman of child bearing potential (WOCBP) must have a negative urine pregnancy test and be using an effective method of birth control such as, but not limited to, birth control pills, contraceptive foam, diaphragm, IUD, vasectomized partner, abstinence, or condoms;
  • Capable of compliance with the required study and sick visits (i.e., no planned travel commitments);
  • Willing to follow study restrictions;
  • Generally in good health based on medical history interview.

Exclusion Criteria:

  • Current participation on any study;
  • Participation in an investigational drug study within 30 days of enrollment;
  • Participation within 30 days of enrollment on any study where the hands were the test site;
  • Pregnancy (as determined by an urine pregnancy test), lactation or planning a pregnancy during the course of the study;
  • Daily smoker;
  • Current or significant history of sinusitis;
  • Skin conditions on the hands or wrists that would interfere with the evaluations, such as scars, tattoos, uneven skin tones, or other conditions;
  • Allergy to soaps, detergents, preservatives, citric acid, malic acid or ethanol;
  • Immunological disorders (i.e., AIDS, HIV, systemic lupus erythematosis, rheumatoid arthritis);
  • Current use or use within 7 days prior to randomization of any antibacterial medications for treatment of respiratory infections;
  • Current use or use within 7 days enrollment of topical drugs (e.g. hydrocortisone or other corticosteroids) to treat skin conditions on the hands or wrists, except for localized treatment of minor cuts or scrapes;
  • Occupational or other requirement for unusually frequent hand washing (i.e. health care worker, food service worker);
  • Currently suffering from respiratory allergies or a history of seasonal respiratory allergies that are normally active during the study period;
  • History of dermatologic disease on the hands, wrists or arms;
  • History of 3rd degree burns and/or skin grafts on the hands or wrists;
  • History of significant or frequent skin and soft tissue infections;
  • Use of androgens, immunomodulators (such as growth factors, systemic corticosteroids, immune globulin, interleukins, interferons) or immunosuppressive medications within 30 days prior to study entry.
  • Erythema score of 1.0 and/or dryness scores on the hands at enrollment of greater than Grade 0;
  • Subject does not experience colds;
  • The subjects from TM&R-0062-08-TXC who were discontinued for irritation, experienced test product related skin reactions or were withdrawn from the study or excluded from the per-protocol analysis for non-compliance.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00993759

Locations
United States, Virginia
University of Virginia
Charlottesville, Virginia, United States, 22908
Sponsors and Collaborators
The Dial Corporation
Hill Top Research
Investigators
Principal Investigator: Ronald Turner, MD University of Virginia
  More Information

No publications provided by The Dial Corporation

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Leslie Lockhart, PhD / Principal Scientist, The Dial Corporation, A Henkel Company
ClinicalTrials.gov Identifier: NCT00993759     History of Changes
Other Study ID Numbers: TM&R-0108-09-TXC
Study First Received: October 8, 2009
Last Updated: October 9, 2009
Health Authority: United States: Food and Drug Administration

Keywords provided by The Dial Corporation:
common cold
rhinovirus
prevention

Additional relevant MeSH terms:
Common Cold
Picornaviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 19, 2014